Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.

Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.

Item
http://www.wikidata.org/entity/Q34321931
Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imagingUsefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatmentAdvanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-upEvaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography.Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinomaEarly Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma.Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience.Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis.Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging.Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS).Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
P2860

Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.

Item
http://www.wikidata.org/entity/Q34321931
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@ast
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@en
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@nl
type
label
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@ast
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@en
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@nl
prefLabel
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@ast
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@en
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Hepatocellular carcinoma treat ...... vents by contrast-enhanced US.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698